B2iDigital
Nov 6, 5:59 PM
Phio Pharmaceuticals Corp. (NASDAQ:
$PHIO ) announced that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Phoenix, Arizona from November 6 to 8, 2026.
Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/phio-pharmaceuticals
John Strasswimmer, M.D., Ph.D., of Florida Atlantic University, lead investigator for the Phase 1b clinical trial, will present the final results on Saturday, November 7, from 2:45 PM to 3:00 PM MST at the Phoenix Convention Center, Halls BC:
• Highlights include final results of the first Phase 1b study assessing the safety and efficacy of INTASYL® PH-762 as a neoadjuvant intratumoral injection for cutaneous carcinomas
• Study findings suggest PH-762 is well-tolerated and may represent a tissue-sparing neoadjuvant to the current cutaneous squamous cell carcinoma treatment standard of Mohs micrographic surgery and/or standard excision
• Additional studies are needed to further evaluate the safety and efficacy of PH-762 and a Phase 2b study is planned for the first half of 2027
In the release, Phio's Chief Executive Officer commented on PH-762 ahead of the SITC presentation.
"The growing body of clinical evidence suggests that PH-762 may offer patients and physicians a meaningful new treatment option capable of shrinking tumors prior to surgery while maintaining an attractive safety profile," said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals.
Read the full release: https://phiopharma.com/phio-pharmaceuticals-announces-invitation-for-oral-presentation-at-41st-annual-sitc-meeting-society-for-immunotherapy-of-cancer/
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company’s website, www.phiopharma.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
